NASDAQ:CAPS Capstone Therapeutics (CAPS) Stock Price, News & Analysis $0.37 -0.01 (-2.63%) Closing price 04:00 PM EasternExtended Trading$0.37 0.00 (-0.81%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Capstone Therapeutics Stock (NASDAQ:CAPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Capstone Therapeutics alerts:Sign Up Key Stats Today's Range$0.36▼$0.3950-Day Range$0.37▼$0.7952-Week Range$0.36▼$3.29Volume308,472 shsAverage Volume5.72 million shsMarket Capitalization$5.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona. Read More Capstone Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreCAPS MarketRank™: Capstone Therapeutics scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCapstone Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCapstone Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Capstone Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Capstone Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capstone Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapstone Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Capstone Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.57% of the float of Capstone Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapstone Therapeutics has a short interest ratio ("days to cover") of 0.53, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Capstone Therapeutics has recently decreased by 45.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapstone Therapeutics does not currently pay a dividend.Dividend GrowthCapstone Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Capstone Therapeutics this week, compared to 5 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capstone Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders59.14% of the stock of Capstone Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.55% of the stock of Capstone Therapeutics is held by institutions.Read more about Capstone Therapeutics' insider trading history. Receive CAPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPS Stock News HeadlinesCapstone Publishes Investor FAQ Detailing 72% Reduction in Convertible Principal and Reaffirming FY2026 GuidanceMay 6 at 7:35 AM | businesswire.comCapstone Awarded Eldorado Stone Distribution, Targeting $5 Million in Organic Revenue GrowthApril 6, 2026 | businesswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 8 at 1:00 AM | Profits Run (Ad)Capstone Expands Commercial Market Reach with KLAD Integration, Unlocking High-Margin, Asset-Light Revenue GrowthMarch 30, 2026 | businesswire.comCapstone unveils new firepit product as it aims for Q2 profitabilityMarch 10, 2026 | msn.comCapstone Expands Retail Portfolio as Order Volume Accelerates; Contractor Demand Drives Repeat Revenue and EBITDA GrowthMarch 10, 2026 | businesswire.comSee who attended KCBJ's 2026 Capstone Awards [PHOTOS]March 9, 2026 | bizjournals.com2026 Capstone Awards: Mixed-use - Merriam Grand StationMarch 7, 2026 | bizjournals.comSee More Headlines CAPS Stock Analysis - Frequently Asked Questions How have CAPS shares performed this year? Capstone Therapeutics' stock was trading at $0.7279 at the beginning of 2026. Since then, CAPS shares have decreased by 49.2% and is now trading at $0.37. How were Capstone Therapeutics' earnings last quarter? Capstone Therapeutics Corp. (NASDAQ:CAPS) released its earnings results on Tuesday, November, 18th. The company reported ($0.35) earnings per share (EPS) for the quarter. The business had revenue of $13.65 million for the quarter. Capstone Therapeutics had a negative trailing twelve-month return on equity of 93.49% and a negative net margin of 45.01%. Read the conference call transcript. When did Capstone Therapeutics IPO? Capstone Therapeutics (CAPS) raised $5 million in an IPO on Thursday, March 6th 2025. The company issued 1,250,000 shares at $4.00 per share. How do I buy shares of Capstone Therapeutics? Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capstone Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capstone Therapeutics investors own include Fulcrum Therapeutics (FULC), Ashford Hospitality Trust (AHT), Assertio (ASRT), Peabody Energy (BTU), PlayAGS (AGS), Astronics (ATRO) and Company Calendar Last Earnings11/18/2025Today5/08/2026Next Earnings (Estimated)5/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CAPS Previous SymbolOTCMKTS:CAPS CIK887151 WebN/A Phone(708) 371-0660Fax602-286-5300Employees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.23 million Net Margins-45.01% Pretax Margin-29.98% Return on Equity-93.49% Return on Assets-39.69% Debt Debt-to-Equity Ratio0.75 Current Ratio1.00 Quick Ratio0.26 Sales & Book Value Annual Sales$48.11 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.27Miscellaneous Outstanding Shares14,440,000Free Float5,899,000Market Cap$5.34 million OptionableN/A Beta-1.52 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CAPS) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredBatten down the hatches – Project Tengu is comingStarting June 16, This AI Lab Could Take Off Dramatically Time magazine recently named this lab "the most d...Chaikin Analytics | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThe $25 trillion opportunity unfolding nowWall Street is calling it a 25 trillion revolution - and it's already underway. Driven by a breakthrough techn...The Oxford Club | SponsoredWhy Elon just bought a power plant (Ticker inside)Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
